255 related articles for article (PubMed ID: 9570525)
1. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.
Macfarlane DE; Manzel L
J Immunol; 1998 Feb; 160(3):1122-31. PubMed ID: 9570525
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies.
Manzel L; Strekowski L; Ismail FM; Smith JC; Macfarlane DE
J Pharmacol Exp Ther; 1999 Dec; 291(3):1337-47. PubMed ID: 10565859
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
4. CpG-oligodeoxynucleotide supports growth of IL-6-dependent 7TD1 murine hybridoma cells.
Manzel L; Macfarlane DE
Life Sci; 1998; 62(1):23-7. PubMed ID: 9444964
[TBL] [Abstract][Full Text] [Related]
5. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
6. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
7. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.
Zhang Z; Weinschenk T; Schluesener HJ
J Neuroimmunol; 2005 Mar; 160(1-2):32-40. PubMed ID: 15710455
[TBL] [Abstract][Full Text] [Related]
8. CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells.
Zhu FG; Marshall JS
J Leukoc Biol; 2001 Feb; 69(2):253-62. PubMed ID: 11272276
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
Wattrang E; Berg M; Magnusson M
Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
[TBL] [Abstract][Full Text] [Related]
10. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides.
Mannon RB; Nataraj C; Pisetsky DS
Cell Immunol; 2000 Apr; 201(1):14-21. PubMed ID: 10805969
[TBL] [Abstract][Full Text] [Related]
12. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
13. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing.
Chu RS; Askew D; Noss EH; Tobian A; Krieg AM; Harding CV
J Immunol; 1999 Aug; 163(3):1188-94. PubMed ID: 10415013
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides.
Zhu FG; Reich CF; Pisetsky DS
J Leukoc Biol; 2002 Dec; 72(6):1154-63. PubMed ID: 12488497
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
17. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.
Gürsel M; Verthelyi D; Gürsel I; Ishii KJ; Klinman DM
J Leukoc Biol; 2002 May; 71(5):813-20. PubMed ID: 11994506
[TBL] [Abstract][Full Text] [Related]
18. CpG DNA and LPS induce distinct patterns of activation in human monocytes.
Hartmann G; Krieg AM
Gene Ther; 1999 May; 6(5):893-903. PubMed ID: 10505115
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in weaned piglets.
Zhang L; Tian X; Zhou F
Int Immunopharmacol; 2006 Oct; 6(10):1623-31. PubMed ID: 16919835
[TBL] [Abstract][Full Text] [Related]
20. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
Kaur H; Jaso-Friedmann L; Leary JH; Praveen K; Brahmi Z; Evans DL
Scand J Immunol; 2005 Oct; 62(4):361-70. PubMed ID: 16253123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]